# PULNOVO MEDICAL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulnovo-medical

- Industry: Medical Devices & Equipment
- Headquarters: Wuxi, China
- Website: www.pulnovomed.com
- Total disclosed funding: $200M
- Latest round: Series D (Apr 19, 2026)
- Investors on record: 7

## About

Based in China, Pulnovo Medical (Wuxi) Co., Ltd., trading as Pulnovo Medical, operates as a medical device developer that provides radiofrequency ablation products for the treatment of pulmonary hypertension. Based in Wuxi, China and founded in 2013 by its founder Cynthia Chen, Pulnovo Medical (Wuxi) Co., Ltd., trading as Pulnovo Medical, is a medical equipment company that engages in the research and development, production, and service of radiofrequency ablation technology products for pulmonary hypertension. It has 11 national clinical centers, and has offices in Shanghai, Wuxi, and production bases in Wuxi. In April 2026, PULNOVO MEDICAL raised USD 100 million in Series D funding led by Medtronic, with participation from EQT Private Capital Asia, Qiming Venture Partners, Gaorong Ventures, OrbiMed Advisors, Lilly Asia Ventures and HSG. The company focuses on pulmonary hypertension, chronic heart failure combined with pulmonary hypertension and other diseases. Its products include multipolar synchronous pulmonary artery radiofrequency ablation catheters and multipolar synchronous pulmonary artery radiofrequency ablation instruments. The catheter transmits the high-frequency current from the radiofrequency ablator to the specified electrode, and the treatment of pulmonary hypertension is achieved by ablating the sympathetic nerve at the target site. The company generates revenue by developing and providing catheters and other devices for the treatment of pulmonary hypertension, chronic heart failure combined with pulmonary hypertension and other diseases. The company will use April 2026 will be used to support ongoing clinical research and development, global regulatory filings, international commercialization, and continued investment in core technology platforms.

## Funding rounds

- Series D, Apr 19, 2026, $100M — EQT, OrbiMed Advisors, Qiming Venture Partners, Lilly Asia Ventures, Medtronic, Gaorong Ventures, HSG
- Series C, Mar 3, 2025, $100M — OrbiMed Advisors, Qiming Venture Partners, Lilly Asia Ventures, Gaorong Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C, Series D
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C, Series D
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C, Series D
- EQT (https://capitalatlas.ai/funds/eqt) — Series D
- Medtronic — Series D
- HSG (https://capitalatlas.ai/funds/hsg) — Series D